Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis
- 1 April 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 185 (2) , 119-122
- https://doi.org/10.1016/s0022-510x(01)00478-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Treatment of myasthenia gravis with mycophenolate mofetil: A case reportMuscle & Nerve, 2000
- MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATIONTransplantation, 1999
- Cellcept enhances the rate of apoptosis in T cells after renal transplantationTransplantation Proceedings, 1999
- Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cellsTransplantation Proceedings, 1999
- Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetilNeurology, 1998
- Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedureClinical Chemistry, 1998
- Mycophenolate MofetilPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997
- Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant RejectionDrug Safety, 1997